Library

Place of publication:
neurology, neuropsychiatry, psychosomatics. 2020; 12 (1): 56–60

Summary:
The purpose of the study is to study the effectiveness and safety of the drug Mexidol ^® Fort 250 in patients with chronic brain ischemia (chemical) against the background of arterial hypertension (hypertension) and atherosclerosis. Patients and methods. The study includes 20 patients suffering from hypertension and atherosclerosis, aged 45 to 75 years who received Mexidol ^® intravenously (500 mg 1 time per day) for 14 days, with the subsequent reception of Mexidol ^® Fort 250 orally in the dose 250 mg 3 times a day for 60 days (main group). The control group consisted of 14 patients with chemicals against the background of a combination of hypertension and atherosclerosis, who were prescribed complex therapy of chemicals without the use of these drugs. Patients were examined before and after 14 and 60 days of treatment. In dynamics, subjective complaints, neurological symptoms, indicators of the Tinetti scale for assessing the motor activity of elderly patients (Functional Mobility Assessment in Elderly Patients) were studied; Montreal scale for assessing cognitive functions (Montreal Cognitive Assessment, Mosa); Hamilton anxiety and depression (Hamilton Anxiety Rating Scale, Hars); Asthenia scales MFI-20 (MultidimenSional Fatigue Inventory); General clinical impression scales (Clinical Global Impression, CGI). Results and discussion. It was established that therapy with Mexidol ^® in patients with chemous and atherosclerosis was accompanied by positive dynamics along the MFI-20 asthenia scales, mosa cognitive functions, as well as the coordination of Tinetti movements. In patients, the control group was not noted for reliable differences in these indicators. Complex treatment of Khim, which included Mexidol ^® and Mexidol ^® Fort 250 in the form of consistent therapy, turned out to be more effective than complex therapy of chemicals without the use of these drugs as a whole by more than 2 times, and for certain values ​​of the parameters of the scales up to 10 times. Conclusion. The results of the study of the drug Mexidol ^® Forte 250 in the framework of consistent therapy used according to the above scheme indicate its clinical efficiency and safety in patients with chemicals. Keywords: chronic brain ischemia; cognitive and motor functions; asthenic and anxious-depressive disorders; Mexidol ^® Fort 250.

¹ FSBI “Scientific Center for Expertise of Medical Application” of the Ministry of Health of Russia, Moscow, Russia;
² FGAOU VO "First Moscow State Medical University named after THEM. Sechenov »Ministry of Health of Russia (Sechenov University), Moscow, Russia;
³ FGAOU in Russian National Research Medical University named after N.I. Pirogov ", Moscow, Russia;
⁴ FGBNU "Federal Scientific Center-the All-Russian Research Institute of Experimental Veterinary Medical Academy of Education named after K.I. Scriabin and Ya.R. Kovalenko of the Russian Academy of Sciences ", Moscow, Russia

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2020, T. 120, No. 12, Issue. 2

Summary:
the stroke remains one of the most urgent problems of modern medicine, which is leading the cause of mortality and disability. In the Russian Federation there is extensive experience in the use of neurocytoprotectors in ischemic stroke. In real clinical practice, it is important to observe the conditions under which neuroprotement will be as safe and effective as possible. This review presents an analysis of the results of clinical studies devoted to the effectiveness and safety of ethylmethylhydroxypyridine of succinate (Mexidol) in patients with acute ischemic stroke. Early (in the first 6 hours of stroke), the use of the drug significantly improves recovery dynamics and improves the outcome of the disease; When using the drug, the acceleration of regression of neurological disorders, improvement of the life and quality of life of patients was noted. The studies showed a high security profile of ethylmethylhydroxypyridine of succinate. Keywords: ischemic stroke, thrombolytic therapy, clinical studies, disability, antioxidant system, ethylmethydlhydroxypirinatin, Mexidol.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2020, T. 120, No. 12

Summary:
the main risk factors for blood circulation diseases and the leading causes of mortality in the world continue to be arterial hypertension, diabetes, obesity and dyslipidemia, and the combination of these diseases significantly increases the likelihood of developing cardio and cerebrovascular pathology. Improving approaches to the diagnosis and therapy of these diseases is a priority problem of modern medicine. Currently, there is no universal drug that allows you to influence all links in the pathological process both in cerebrovascular diseases and in diabetes mellitus, and the problem of rational use of drugs in patients with co -filled pathology has not been completely resolved. The difficult clinical task is not only in the timely detection of the disease and making the correct diagnosis, but also in choosing the safest and most effective drug. A number of clinical studies showed the effectiveness of Mexidol in the treatment of this category of patients, which is determined by its complex, playotropic and multimodal mechanism of action. Key words: cerebrovascular diseases, diabetes mellitus, metabolic syndrome, antioxidants, Mexidol.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2020, T. 120, No. 11

Summary:
Purpose of the study. Studying the effectiveness and safety of consistent therapy with Mexidol drugs (injections intravenously for 14 days - a saturation phase) and Mexidol Forte 250 (tablets for 60 days - the phase of maximization of the therapeutic effect) in patients with chronic brain ischemia (chemical) against the background of arterial hypertension and atherosclerosis. Material and methods. In the group of therapy with Mexidol, 27 patients were observed (24 women and 3 men) with Khim I-II century. Against the background of a combination of arterial hypertension and atherosclerosis, which is treated with Mexidol with the drug intravenously (500 mg once a day) for 14 days with the subsequent intake of Mexidol Forte 250 in a daily dose of 750 mg (1 tablet 3 times a day) for 60 days) . The comparison group consisted of 30 patients (22 women and 8 men) with KhMI I-II century, comparable by age, the nature of risk factors and the severity of neurological manifestations. Patients of both groups received basic therapy to correct their risk factors. They assessed the state of motor activity (Tinetti test), cognitive functions (MOCA Test), anxiety and depression (Hamilton's depression scale), a general clinical impression scale. Results and conclusion. The inclusion of Mexidol and Mexidol Forte 250 in the form of consistent prolonged therapy is the inclusion of chemical therapy in the standard therapy. The results indicate more clinical efficiency and sufficient safety of combined therapy. By the end of the study (on the 74th day), patients of the therapy group of Mexol with the drug, a reliable improvement in motor activity, cognitive functions of the emotional sphere, as well as a decrease in fatigue and neurological manifestations in comparison with a comparison group, was noted. Key words: chronic brain ischemia, Mexidol, Mexidol Forte 250.

ANO "Central Clinical Medicine-Sanitary Part", Magnitogorsk, Russia

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2020, T. 120, No. 10

Summary:
Purpose of the study. Evaluate the effectiveness and safety of consistent therapy with Mexidol drugs (a solution for iv and iv in the administration) and Mexidol Forte 250 (tablets covered with a shell) in patients with a hemispherral ischemic stroke in an acute and early recovery periods. Material and methods. At the time of the end of the therapy, the dynamics on the modified Rankin scale (MRS), the test results on the stroke of the National Institute of Health (NIHSS), the Bartel (BI), the Montreal Cognitive Functions Assessment (MOCA), the BEK questionnaire (BDI), the questionnaire questionnaire (BDI). Evaluation of the quality of life (EQ-5D). Results and conclusion. Consistent long -term therapy with Mexidol with a dosage of 500 mg/day for 14 days (saturation phase) and Mexol Forte 250 by 250 mg 3 times a day for 60 days (phase of maximization of the therapeutic effect) provides additional opportunities for more complete restoration in acute and acute and acute and acute The early recovery periods of the hemisphere stroke (improves the quality of life, improves the restoration of motor and cognitive functions). Keywords: Holding ischemic stroke, Mexidol Fort 250, acute and early recovery periods, quality of life.

Place of publication:
New therapeutic magazine "Non Nocera", September, 2020

Summary:
In recent decades around the world, significant changes in the age structure of the population have occurred: a group of people from 60 years has grown at a higher rate, and therefore the prevention and treatment of diseases in older people are one of the most important tasks of modern medicine. With age in the entire body, and especially in the nervous system, there are anatomical and functional changes and disorders of various biological processes, leading to a deterioration in the blood supply to the brain and subsequent change in the small cerebral vessels (micro- and macroangiopathy), which leads to a decrease in microcirculatory blood flow, a change in vascular walls.

Authors:
L.V. Stakhovskaya ¹ , E.A. Mkhitaryan ² , O.N. Tkachev ^1.2 , T.M. Ostroumova ³ , O.D. Ostroumova ^3,

¹ FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia;
² Russian Gerontological Scientific and Clinical Center of the FGAOU in the Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia;
³ FGAOU in the First Moscow State Medical University named after THEM. Sechenov »Ministry of Health of Russia (Sechenov University), Moscow, Russia;
⁴ FSBEI of DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia, Moscow, Russia

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2020, T. 120, No. 8, Issue. 2

Summary:
Purpose of the study. To evaluate the effectiveness and safety of prolonged sequential therapy with Mexidol with a hemisphere ischemic stroke in acute and early recovery periods in patients of various age groups. Material and methods. The study is an additional analysis of age groups among 150 patients who took part in a randomized double blind multicenter placebo-controlled in parallel groups of the epic study. The entire study of the study (62 men and 88 women) was divided into subgroups by age: under 60 years old, 60–75 years old, 76–90 years. Also, all participants in the study were divided into 2 populations: ITT (Intent to Treat Population, patients who received at least one dose of the drug/placebo drug) and PP (Per Protocol Population, patients who received the drug in accordance with the research protocol). The results were evaluated on the modified Rankin scale (MSHR) at the end of the course of therapy, the Bartel index, the Bek depression scale, and the European questionnaire for assessing the quality of life. Results. The effectiveness of Mexidol on all the scales used did not differ depending on age. At the time of the end of the therapy, the average MSHR score was lower in patients 76–90 years (in both populations) compared to placebo (p <0.001). The dynamics of reducing the average score in MSHR (1-5th visits) was more pronounced in patients of 60–75 years (p = 0.025), including patients with diabetes. In patients 76–90 years old and patients with diabetes mellitus compared to placebo, the severity of cognitive-affective symptoms of depression (p = 0.049 and p = 0.02, respectively), the share of patients with lack of problems with everyday affairs, increased statistically significant (P = P = P = P = P = P = P = P = P = P = P. 0.007 and p = 0.02, respectively). In patients with diabetes, the level of everyday activity (p = 0.023) has also increased statistically significantly significantly increased and the quality of life has improved (p = 0.045). There were no reliable differences in the frequency of unwanted phenomena in all studied groups. Conclusion. It is recommended that the use of Mexidol in the acute and early recovery periods of ischemic stroke in all age groups, including patients with diabetes mellitus. Key words: ischemic stroke, Mexidol, ethylmethylhydroxypyridine succinate, effectiveness and safety, ischemic stroke, acute period, early recovery period, epic.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova 2020, T. 120, No. 8, S. 1-7

Summary:
Vascular cognitive disorders (TFR) are one of the urgent problems of clinical neurology and the second most common cause of dementia. TFR cover a number of disorders in which vascular factors cause or contribute to a decrease in cognitive functions. Among the main risk factors for the development of the Investigative Committee, elderly age and vascular factors are considered, leading to endothelial dysfunction and damage, which in turn can cause neurovascular dysfunction, increased permeability of the hematoencephalic barrier and microsyuded thrombosis. One of the most important mechanisms for the development of the Investigative Committee is oxidative stress, which indicates the need to use agents with antioxidant activity. Such drugs include Mexidol (ethylmethylhydroxypyridine succinate). Mexidol has pronounced antioxidant and antihypoxic properties. The clinical effectiveness of Mexidol in relation to the Investigative Committee was established in many studies. Key words: chronic cerebrovascular failure, oxidant stress, vascular cognitive impairment, endothelial dysfunction, Mexidol.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2020, T. 120, No. 6

Summary:
Chronic brain ischemia (Khim) - a common cerebrovascular syndrome, the development of which is associated with a high risk of increasing cognitive, behavioral, motor disorders, the formation of the patient's dependence on outsider. The timely start of treatment can slow down the course of the disease, make it more favorable. The review presents an analysis of the results of clinical studies devoted to the effectiveness of ethylmethylhydroxypyridine of succinate (Mexidol) in patients with chemicals. The effectiveness of the drug was noted when stopping cognitive, affective and motor disorders. Information about good tolerance of ethylmethylhydroxypyridine of succinate is given. Keywords: chronic brain ischemia, cognitive disorders, affective disorders, ethylmethylhydroxypyridine succinate, mexidol, treatment.

Place of publication:
therapy No. 6 (40) 2020

Summary:
the purpose of the study is to evaluate the effectiveness, safety and the possibility of correcting the neuropsychiatric manifestations of chronic brain ischemia (chemical) drugs Mexidol ^® and Mexidol ^® Forte 250 within the framework of consecutive therapy against the background of arterial hypertension, atherosclerosis (IBS), osteoarthritis or OA) or OA) or OA) rheumatoid arthritis (RA). Material and methods. 134 patients 45–75 years old with a neuroimulated chemical chemicized, combined with hypertension, coronary heart disease and articular pathology were examined. Group 1 (observations) included 79 patients - 30 patients with RA (subgroup 1A) and 49 with the ot of the knee joints (subgroup 1b), who received in the complex therapy Mexidol ^® and Mexidol ^® Fort 250. Group 2 (control) amounted to 55 patients - 25 patients with RA (subgroup 2A) and 30 - with OA (subgroup 2B), which used to use basic therapy without the addition of Mexidol. The dynamics of subjective and physical symptoms were evaluated, values ​​on the scales of CGI, Mosa, MFI 20, anxiety and depression of Hamilton, Tinnetti. Mexidol ^® was prescribed intravenously (500 mg per day) for 14 days with the subsequent oral administration of the drug Mexidol ^® Fort 250 at 250 mg 3 times/day another 60 days. Results. ^® and Mexidol ^® to the standard treatment of drugs in the framework of consistent therapy contributed to an increasing improvement in all studied indicators. In the control groups, the cognitive status did not change. The use of initiating intravenous therapy with Mexidol increased the adherence of patients to the prolonged use of the drug. Conclusion. Violations of the locomotor function in polymorbid patients are partially associated with chemicals. The additional purpose of the consistent infusion and tablet forms of Mexidol significantly improves cognitive functions with the correction of the stability of walking, asthenic manifestations, and increases the motivation for active life. Key words: chronic brain ischemia, Mexidol ^® , Mexidol ^® Fort 250, osteoarthritis, rheumatoid arthritis, arterial hypertension, coronary heart disease.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova 2020, T. 120, No. 3, P. 87-91

Summary:
an analysis of the clinical efficiency and safety of the use of ethylmethylhydroxypyridine of succinate (Mexidol) in a complex of rehabilitation measures in patients who have undergone ischemic stroke (AI). It is shown that with the terminal use of the drug in patients, restoration of neurological functions is improved, regression of neurological deficiency and cognitive disorders, including improving memory, reducing the manifestation of asthenic syndrome, increasing the level of socio-household adaptation, and improving the psychoemotional state of patients, a decrease in spasticity, increasing spasticity, and increasing the motor and speech activity, praxis, reliable elimination of ignoring syndrome. In patients who have suffered AI, there was a decrease in the blood level of total cholesterol and low-density С-lipoproteins, a decrease in the severity of hypercoagulation. The results of the studies convincingly showed the feasibility of using ethylmethylhydroxypyridine of succinate (Mexidol) at all stages of restoration treatment of patients who suffered AI. Keywords : ethylmethylhydroxypyrididine succinate, Mexidol, rehabilitation, recovery, stroke.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2020, T. 120, No. 3 issue. 2

Summary:
Purpose of the study. Assessment of the effectiveness and safety of prolonged sequential therapy with Mexidol and Mexidol Forte 250 for a functional outcome in patients with ischemic stroke (AI) in the basin of the internal carotid artery. Material and methods. The study includes 50 patients with the first AI in the carotid pool, which were hospitalized in the SOKB on the 1st day from the onset of the disease. Patients of the main group (n = 25) received Mexidol 500 mg intravenously dropped 1 time per day for 14 days, then Mexidol Forte 250 in tablets of 250 mg 3 times a day for 60 days. Patients of the comparison group (n = 25) received standard basic therapy. The reliability of intergroup differences was evaluated using the Mann-Uiite criterion, the exact criterion of Fisher, and the calculation of relative risk (OR). Statistically significant were the differences at the level of p <0.05. Results. After 14 days of therapy, both groups of patients demonstrated positive dynamics regarding the initial indicators. At the same time, patients who received Mexidol had a higher score on the MOS scale (U = 173.5, P = 0.006) showed a lower score when performing tasks for dynamic praxis (U = 214.0, P = 0.028) and optical Spatial disorders (U = 170.5, p = 0.003), the better strength of memorization (181.5, p = 0.006), and also better performed tasks for generalization (U = 200.5, p = 0.014). By the 74th day, the absence of moderate cognitive disorders (MOS> 26 points) was diagnosed in 17 (68%) patients of the main group and 14 (56%) patients of the comparison group. Differences without a statistically significant difference. At the same time, patients of the main group had a statistically lower score on the NIHSS scale (U = 124.0, p <0.001) and a lower degree of disability: the total score on the MRS 0-2 scale was reached in 19 (76%) patients of the main group and only In 12 (48%) patients of the comparison group (OR = 3.34, F = 0.07, P <0.05). Also, patients who received prolonged sequential therapy with Mexidol and Mexidol Forte 250 had more mild spatial disorders than patients of the comparison group. Conclusion. Conducting consistent therapy with Mexidol and Mexol Forte 250 in the acute and early recovery periods of AI positively affects the regression of focal neurological symptoms, increases the likelihood of independence in everyday life by 3.34 times, and helps to reduce the severity of optical, neurodynamic disorders and memory impairment. Key words: ischemic stroke, Mexidol, Mexidol Fort 250, cognitive impairment, functional outcome.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova 2020, T. 120, No. 3, Issue. 2, S. 60-65

Summary:
Purpose of the study. Studying the effectiveness and safety of therapy with Mexidol, used intravenously (500 mg 1 time per day) for 14 days, with the subsequent administration of orally, Mexidol Forte 250 in a dose of 250 mg (1 tablet) 3 times a day for 60 days in patients with patients with Chronic ischemia of the brain (Khim) against the background of arterial hypertension and atherosclerosis of brachiocephalous arteries. Material and methods. The observation program includes 52 patients with an established diagnosis of chemicals confirmed by neuroizializational research methods. The main group included 26 patients who, in addition to basic therapy, Mexidol and Mexidol Forte 250. The comparison group consisted of 26 patients who received only basic therapy. Results and conclusion. The high efficiency and safety of consistent therapy (parenteral administration and then taking the tablet form of the drug Mexidol Forte 250) are shown. Against the background of treatment, an improvement in emotional and cognitive statuses, a decrease in static-locomotor disorders, as well as the severity of subjective neurological symptoms is noted. The high commitment of patients on the therapy is shown. Keywords: chronic brain ischemia, arterial hypertension, atherosclerosis of brachiocephalous arteries, Mexidol, Static-Locomotor disorders, cognitive disorders.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2019, T. 119, No. 12, Issue. 2

Summary:
Purpose of the study. The study of the effectiveness and safety of therapy with Mexidol, prescribed intravenously (500 mg 1 time per day) for 14 days, followed by the oral administration of Mexidol Forte 250 in 250 mg 3 times a day in patients with chronic brain ischemia (chemical). Material and methods. The study includes 56 patients with chemicals, which developed against the background of a combination of arterial hypertension and atherosclerosis. They evaluated the results of physical examination methods (level of blood pressure, heart rate, etc.), complaint dynamics, indicators on the scales of the general clinical impression (CGI), Mosa, asthenia MFI 20, anxiety and depression of Hamilton, Tinnetti. Results and conclusion. The results of the study showed the effectiveness and safety of intravenous administration of Mexidol, followed by the oral administration of Mexidol Forte 250. The specified scheme of therapy contributed to the regression of objective and subjective symptoms of HIM, and led to improvement in the emotional, cognitive and motor spheres. Key words: chronic brain ischemia, atherosclerosis, arterial hypertension, motor disorders, cognitive disorders, Mexidol, Mexidol Fort 250.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2019, T. 119, No. 9

Summary:
Purpose of the study. Studying the effectiveness and safety of therapy with a medicine (LP) Mexidol, used intravenously (500 mg 1 time per day) in the form of infusions for 14 days, followed by orally orally Mexidol Fort 250 in a dose of 250 mg (1 tablet) 3 times a The day for 60 days in patients with chronic ischemia of the brain against the background of arterial hypertension and atherosclerosis. Material and methods. The open observation program includes 60 patients with an established diagnosis of chronic brain ischemia, confirmed by neuroimaging research methods. Results and conclusion. The results of the study showed high efficiency and safety of sequential therapy (injections and then taking the tablet form of the LP Mexol Forte 250). Against the background of treatment, an improvement in emotional and cognitive status, a decrease in motor disorders, as well as the severity of subjective manifestations are noted. High commitment to patients to the therapy is shown. Keywords: chronic brain ischemia, arterial hypertension, atherosclerosis, ethylmethylhydroxypyrididine succinate, mexidol, cognitive disorders.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2019, T. 119, No. 8

Summary:
one of the leading causes of mortality, disability and pronounced maladaptation of patients is an ischemic stroke, which accounts for about 80% of all types of acute cerebrovascular accident. At the same time, approximately 2/3 of patients detect residual phenomena of cerebrovascular circulation disorders of varying degrees of severity. Currently, the problem of ischemic stroke is given great attention, and one of the aspects of work in this area is the developed international and domestic recommendations for the prevention of stroke, treatment and rehabilitation of patients who have undergone stroke. The article provides an overview of the latest clinical recommendations for the early management of patients with acute ischemic stroke of the American Association on the Problems of the Heart and the American Association for the Treatment of Stroke, as well as the features of the therapy and prevention of stroke in Russia, European and the USA. Key words: ischemic stroke, clinical recommendations, therapy of ischemic stroke.